Day One Biopharmaceuticals Reports Strong Revenue Growth and Acquisition

Written by Emily J. Thompson, Senior Investment Analyst

Source: Business Insider

Updated: Oct 30 2024

0mins

Source: Business Insider

Day One Biopharmaceuticals Inc shares surged by 25.62% as the stock crossed above its 5-day SMA, reflecting positive investor sentiment.

The company reported a preliminary net product revenue of $155.4 million for 2025, marking a 172% year-over-year increase, driven by strong demand for its treatment OJEMDA™ for pediatric low-grade glioma. Additionally, the acquisition of Mersana for $25 per share is expected to enhance Day One's oncology pipeline, particularly with the innovative Emi-Le program targeting rare cancers, further solidifying its market position.

This impressive revenue growth and strategic acquisition position Day One favorably for future expansion, with projected revenues for 2026 expected to reach between $225 million and $250 million, indicating a strong commitment to developing new therapies and addressing unmet medical needs.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Let AI Trade for You

Auto Trading Task on NVDA?

Get Started Free